The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- Study type
- Review article
- Study name
- WHO CNS5 2021
- Design
- Review article (summary of the fifth edition of the WHO classification of tumours of the central nervous system)
- Sample size
- Not applicable (review article)
- Source
- Neuro-Oncology · 2021
In plain words
Every few years the World Health Organization updates the way tumours of the brain and spinal cord are named and grouped. In the 2021 edition, besides looking under the microscope, molecular tests also play a bigger part in diagnosis. This helps doctors make a more accurate and consistent diagnosis. Talk over the details of your diagnosis and treatment with your treating doctor.
Study population
No clinical study was performed; this article reviews the classification of tumours of the brain and spinal cord.
Endpoints
This is a review article and has no clinical endpoint. Its aim is to summarise the general changes of the fifth edition of the 2021 classification and the specific changes in each taxonomic category.
Safety and side effects
According to the abstract, safety is not addressed in this review article.
Clinical significance and place in guidelines
According to the abstract, the fifth edition increases the role of molecular diagnostics in the classification of CNS tumours, emphasises integrated diagnoses and layered reports, establishes different approaches to nomenclature and grading, and introduces new types and subtypes (some based on DNA methylome profiling). Details of the changes in each category and their practical implications should be checked in the full text and in the fifth edition itself.
Limitations
This article is a summary of the classification and does not replace a full study of the fifth WHO edition. The abstract gives no quantitative data or assessment of clinical impact.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.